Jeff Martin
Stock Analyst at Roth Capital
(4.34)
# 391
Out of 5,113 analysts
65
Total ratings
59.02%
Success rate
16.28%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BWMN Bowman Consulting Group | Maintains: Buy | $45 → $50 | $35.57 | +40.57% | 6 | Dec 9, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $280 → $292 | $266.98 | +9.37% | 17 | Dec 1, 2025 | |
| PERI Perion Network | Reiterates: Buy | $14 → $15 | $9.91 | +46.32% | 10 | Nov 13, 2025 | |
| NSP Insperity | Maintains: Buy | $85 → $74 | $39.44 | +87.63% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $16.97 | +59.10% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $4.12 | +21.51% | 1 | May 14, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $4.43 | +103.16% | 1 | Mar 20, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $37.00 | +21.62% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $20.01 | +49.93% | 6 | Nov 5, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $0.89 | +647,891.90% | 2 | Nov 15, 2017 |
Bowman Consulting Group
Dec 9, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $35.57
Upside: +40.57%
OSI Systems
Dec 1, 2025
Maintains: Buy
Price Target: $280 → $292
Current: $266.98
Upside: +9.37%
Perion Network
Nov 13, 2025
Reiterates: Buy
Price Target: $14 → $15
Current: $9.91
Upside: +46.32%
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $39.44
Upside: +87.63%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $16.97
Upside: +59.10%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $4.12
Upside: +21.51%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $4.43
Upside: +103.16%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $37.00
Upside: +21.62%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $20.01
Upside: +49.93%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $0.89
Upside: +647,891.90%